Infergen whiffs in phase-3 HCV trial despite the PR’s saying the trial was “positive” in the header. The SVR rate on an ITT basis was 11% in the high-dose arm and 7% in the low-dose arm, which are hardly results to boast about even in the second-line setting. Of course, the PR talks as much as possible about subset data:
Infergen (a/k/a/ consensus interferon) is a drug that no one seems to want (for good reason, IMO). AMGN licensed it to ITMN in 2001; ITMN then sold it to VRX who sold it to Three Rvers Pharma, the current owner.
Market Data 
Markets 
AI
